Division of Surgical Oncology, Comprehensive Cancer Center, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC, USA.
Department of Surgical Oncology, Mayo Clinic in Florida, Jacksonville, FL, USA.
Ann Surg Oncol. 2023 Jun;30(6):3413-3422. doi: 10.1245/s10434-023-13189-w. Epub 2023 Mar 1.
Complete resection of colorectal liver metastasis (CLM) improves long-term survival in colorectal cancer. However, there is limited recent data on conditional survival (CS) as postoperative survival milestones are achieved post-hepatectomy.
A retrospective analysis was performed on the penta-institutional Colorectal Liver Operative Metastasis International Collaborative (COLOMIC), with 906 consecutive CLM hepatectomy cases. CS was calculated using Bayes' theorem and Kaplan-Meier analysis. Additional CS analyses were performed on additional clinicopathologic risk factors, including colon cancer laterality, KRAS mutation status, and extrahepatic disease.
The 5-year CS was 40.6%, 45.3%, 52.8%, and 65.3% at 0, 1, 2, and 3 years postoperatively, with significant improvements each year (p < 0.005). CS was not significantly different between right-sided and left-sided colorectal cancers by 3 years postoperatively. Patients with KRAS mutations had worse CS at all timepoints (p < 0.001). Extrahepatic disease was a poor prognostic factor for OS and CS (p < 0.001). However, CS for patients with KRAS mutations or extrahepatic disease improved significantly as 2-year, postoperative survival was achieved (p < 0.05).
Five-year CS after hepatectomy for CLM improved with each passing year of survival postoperatively. Although extrahepatic disease and KRAS mutations are poor prognostic factors for OS, these populations still had improved CS after 2 years postoperatively.
结直肠肝转移(CLM)的完全切除可改善结直肠癌患者的长期生存。然而,由于肝切除术后达到了术后生存的里程碑,关于条件生存(CS)的最新数据有限。
对五家机构的结直肠肝手术转移国际协作(COLOMIC)进行了回顾性分析,共有 906 例连续的 CLM 肝切除术病例。使用贝叶斯定理和 Kaplan-Meier 分析计算 CS。对包括结肠癌侧别、KRAS 突变状态和肝外疾病在内的其他临床病理危险因素进行了额外的 CS 分析。
术后 0、1、2 和 3 年的 5 年 CS 分别为 40.6%、45.3%、52.8%和 65.3%,每年均有显著改善(p<0.005)。术后 3 年内,右半结肠癌和左半结肠癌的 CS 无显著差异。KRAS 突变患者在所有时间点的 CS 均较差(p<0.001)。肝外疾病是 OS 和 CS 的不良预后因素(p<0.001)。然而,KRAS 突变或肝外疾病患者的 CS 在达到 2 年术后生存后显著改善(p<0.05)。
CLM 肝切除术后 5 年 CS 随术后生存时间的推移而提高。尽管肝外疾病和 KRAS 突变是 OS 的不良预后因素,但这些人群在术后 2 年仍有改善的 CS。